NRXP

NRx Pharmaceuticals, Inc. [NRXP] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

NRXP Stock Summary

Top 10 Correlated Stocks

NRXP

In the News

NRXP Financial details

Company Rating
-
Market Cap
49M
Income
-31.75M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
14 May 2024
P/E
-1.05
Forward P/E
-
PEG
0.54
P/S
-
P/B
-5.61
P/C
-
P/FCF
-1.35
Quick Ratio
0.46
Current Ratio
0.68
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.44
EPS next Y
-
EPS next Q
-
EPS this Y
637.04%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-30.27%
-
-
-
-
SMA20
3.67%
SMA50
-23.91%
SMA100
-15.04%
Inst Own
-
Inst Trans
-
ROA
-253%
ROE
6977%
ROC
5.36%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.21-12.0
52W High
-81.08%
52W Low
+13.5%
RSI
46.53
Rel Volume
8.68
Avg Volume
172.16K
Volume
1.49M
Perf Week
-7.35%
Perf Month
-5.81%
Perf Quarter
-22.53%
Perf Half Y
-24.58%
-
-
-
-
Beta
0.988
-
-
Volatility
0.07%, 0.18%
Prev Close
5.58%
Price
2.27
Change
5.09%

Something similar

Top by Market Cap
CMC.DE
AAPL
LLY.SW
3V64.DE
META
Same Sector
INSP
CEMI
300760.SZ
0UNL.L
CBX.L
Top Correlated Stocks
ROHLTD.NS
JSM
KESORAMIND.NS
M&MFIN.NS
TEXRAIL.NS
Similar Market Cap
AIGYX
WIMI
0LHX.L
IAE
NVBW

Company Profile

Healthcare Biotechnology
  • Volume Average 172.16K
  • Market Capitalization 49M
  • Employee 2
  • CEO Mr. Stephen H. Willard Esq.
  • Headquarters Wilmington,DE,US
  • IPO Date 2017-12-04
  • Website https://www.nrxpharma.com

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.